Efficacy and tolerability of BMS 650032 + peginterferon alfa-2a + ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C

Trial Profile

Efficacy and tolerability of BMS 650032 + peginterferon alfa-2a + ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2012

At a glance

  • Drugs Asunaprevir; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Apr 2012 Results will be presented at EASL-2012 according to a Bristol-Myers Squibb media release.
    • 04 Apr 2011 New trial record
    • 03 Apr 2011 Results presented at the 46th Annual Meeting of the European Association for the Study of the Liver.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top